• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again.

作者信息

Prins Kurt W, Thenappan Thenappan, Weir E Kenneth, Kalra Rajat, Pritzker Marc, Archer Stephen L

机构信息

1 Cardiovascular Division University of Minnesota Medical School Minneapolis MN.

2 Department of Medicine Queen's University Kingston ON.

出版信息

J Am Heart Assoc. 2019 Jan 8;8(1):e011343. doi: 10.1161/JAHA.118.011343.

DOI:10.1161/JAHA.118.011343
PMID:30590974
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6405714/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5535/6405714/701d3c80b08a/JAH3-8-e011343-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5535/6405714/50ec6265e6ea/JAH3-8-e011343-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5535/6405714/f7aa366b3e31/JAH3-8-e011343-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5535/6405714/46c44290607f/JAH3-8-e011343-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5535/6405714/7b0d79d3367e/JAH3-8-e011343-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5535/6405714/6bd828532a38/JAH3-8-e011343-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5535/6405714/701d3c80b08a/JAH3-8-e011343-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5535/6405714/50ec6265e6ea/JAH3-8-e011343-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5535/6405714/f7aa366b3e31/JAH3-8-e011343-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5535/6405714/46c44290607f/JAH3-8-e011343-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5535/6405714/7b0d79d3367e/JAH3-8-e011343-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5535/6405714/6bd828532a38/JAH3-8-e011343-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5535/6405714/701d3c80b08a/JAH3-8-e011343-g006.jpg

相似文献

1
Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again.药物重新定位用于治疗肺动脉高压：旧药新用
J Am Heart Assoc. 2019 Jan 8;8(1):e011343. doi: 10.1161/JAHA.118.011343.
2
Treatment initiation in paediatric pulmonary hypertension: insights from a multinational registry.儿童肺动脉高压的治疗起始：来自多国注册研究的见解
Cardiol Young. 2017 Aug;27(6):1123-1132. doi: 10.1017/S1047951116002493. Epub 2016 Dec 20.
3
Pulmonary Vascular Distensibility Predicts Pulmonary Hypertension Severity, Exercise Capacity, and Survival in Heart Failure.肺血管扩张性可预测心力衰竭患者的肺动脉高压严重程度、运动能力及生存率。
Circ Heart Fail. 2016 Jun;9(6). doi: 10.1161/CIRCHEARTFAILURE.115.003011.
4
Ventricular Diastolic Pressure Ratio as a Marker of Treatment Response in Pulmonary Hypertension.心室舒张压比值作为肺动脉高压治疗反应的标志物
Chest. 2017 Nov;152(5):980-989. doi: 10.1016/j.chest.2017.05.008. Epub 2017 May 17.
5
Correlation between right ventricular indices and clinical improvement in epoprostenol treated pulmonary hypertension patients.依前列醇治疗的肺动脉高压患者右心室指标与临床改善之间的相关性。
Echocardiography. 2005 May;22(5):374-9. doi: 10.1111/j.1540-8175.2005.04022.x.
6
Right ventricular function assessed by two-dimensional strain and tissue Doppler echocardiography in patients with pulmonary arterial hypertension and effect of vasodilator therapy.二维应变和组织多普勒超声心动图评估肺动脉高压患者右心室功能及血管扩张剂治疗的效果
Am J Cardiol. 2006 Aug 15;98(4):530-4. doi: 10.1016/j.amjcard.2006.02.060. Epub 2006 Jun 27.
7
Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials.肺动脉高压特异性治疗在肺动脉高压中的疗效和安全性：一项随机对照试验的荟萃分析。
Chest. 2016 Aug;150(2):353-66. doi: 10.1016/j.chest.2016.03.031. Epub 2016 Apr 2.
8
Recent advances in the treatment of pulmonary hypertension.肺动脉高压治疗的最新进展
Hellenic J Cardiol. 2005 May-Jun;46(3):165-73.
9
Treatment of pulmonary arterial hypertension with sildenafil: from pathophysiology to clinical evidence.西地那非治疗肺动脉高压：从病理生理学到临床证据
J Cardiothorac Vasc Anesth. 2006 Oct;20(5):722-35. doi: 10.1053/j.jvca.2005.12.011. Epub 2006 Apr 5.
10
Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension-targeted therapy: the EURO-MR study.肺动脉高压靶向治疗患者右心室功能的心脏磁共振成像测量变化：EURO-MR 研究。
Circ Cardiovasc Imaging. 2014 Jan;7(1):107-14. doi: 10.1161/CIRCIMAGING.113.000629. Epub 2013 Oct 30.

引用本文的文献

1
HNRNPA2B1: a novel target in pulmonary arterial hypertension.HNRNPA2B1：肺动脉高压的一个新靶点。
Front Cardiovasc Med. 2025 Jul 9;12:1497938. doi: 10.3389/fcvm.2025.1497938. eCollection 2025.
2
Proteomic and metabolomic profiling nominates druggable targets and biomarkers for pulmonary arterial hypertension-associated myopathy and exercise intolerance in male monocrotaline rats.蛋白质组学和代谢组学分析确定了可成药靶点以及与雄性野百合碱诱导大鼠肺动脉高压相关肌病和运动不耐受相关的生物标志物。
J Heart Lung Transplant. 2025 Jul 10. doi: 10.1016/j.healun.2025.06.034.
3
TNF drives aberrant BMP signaling to induce endothelial and mesenchymal dysregulation in pulmonary hypertension.

本文引用的文献

1
IL-1 Blockade Reduces Inflammation in Pulmonary Arterial Hypertension and Right Ventricular Failure: A Single-Arm, Open-Label, Phase IB/II Pilot Study.白细胞介素-1阻断可减轻肺动脉高压和右心室衰竭中的炎症：一项单臂、开放标签的1B/II期试点研究。
Am J Respir Crit Care Med. 2019 Feb 1;199(3):381-384. doi: 10.1164/rccm.201809-1631LE.
2
Smooth muscle cell-specific FoxM1 controls hypoxia-induced pulmonary hypertension.平滑肌细胞特异性 FoxM1 控制低氧诱导的肺动脉高压。
Cell Signal. 2018 Nov;51:119-129. doi: 10.1016/j.cellsig.2018.08.003. Epub 2018 Aug 6.
3
Pulmonary hypertension: the unaddressed global health burden.
肿瘤坏死因子驱动异常的骨形态发生蛋白信号传导，以诱导肺动脉高压中的内皮细胞和间充质细胞失调。
JCI Insight. 2025 Jun 26;10(14). doi: 10.1172/jci.insight.174456. eCollection 2025 Jul 22.
4
The Use of Apabetalone in Reducing Cardiovascular Outcomes, Based on the Current Evidence and Trials.基于当前证据和试验，阿伐贝酮在降低心血管疾病结局方面的应用
Eur Cardiol. 2025 Feb 28;20:e04. doi: 10.15420/ecr.2023.38. eCollection 2025.
5
Ferroptosis-Mediated Inflammation Promotes Pulmonary Hypertension.铁死亡介导的炎症促进肺动脉高压。
Circ Res. 2024 Nov 8;135(11):1067-1083. doi: 10.1161/CIRCRESAHA.123.324138. Epub 2024 Oct 18.
6
Current Overview of the Biology and Pharmacology in Sugen/Hypoxia-Induced Pulmonary Hypertension in Rats.苏根/低氧诱导的大鼠肺动脉高压的生物学和药理学的最新概述。
J Aerosol Med Pulm Drug Deliv. 2024 Oct;37(5):241-283. doi: 10.1089/jamp.2024.0016.
7
Use of combined chemotherapy and immunotherapy improves pulmonary arterial hypertension.联合化疗和免疫疗法的使用可改善肺动脉高压。
Pulm Circ. 2024 Sep 2;14(3):e12426. doi: 10.1002/pul2.12426. eCollection 2024 Jul.
8
Pulmonary hypertension and the potential of 'drug' repurposing: A case for African medicinal plants.肺动脉高压与药物重新利用的潜力：以非洲药用植物为例
Afr J Thorac Crit Care Med. 2024 Jul 4;30(2):e1352. doi: 10.7196/AJTCCM.2024.v30i2.1352. eCollection 2024.
9
Integrated bioinformatics analysis and experimental animal models identify a robust biomarker and its correlation with the immune microenvironment in pulmonary arterial hypertension.综合生物信息学分析和实验动物模型确定了一种强大的生物标志物及其与肺动脉高压免疫微环境的相关性。
Heliyon. 2024 Apr 16;10(8):e29587. doi: 10.1016/j.heliyon.2024.e29587. eCollection 2024 Apr 30.
10
Multifunctional nanoparticle-mediated combining therapy for human diseases.多功能纳米颗粒介导的人类疾病联合治疗。
Signal Transduct Target Ther. 2024 Jan 1;9(1):1. doi: 10.1038/s41392-023-01668-1.
肺动脉高压：未得到解决的全球健康负担。
Lancet Respir Med. 2018 Aug;6(8):577-579. doi: 10.1016/S2213-2600(18)30268-6. Epub 2018 Jun 29.
4
Network-based approach to prediction and population-based validation of in silico drug repurposing.基于网络的药物重定位预测方法及基于人群的验证。
Nat Commun. 2018 Jul 12;9(1):2691. doi: 10.1038/s41467-018-05116-5.
5
NEDD9 targets to promote endothelial fibrosis and pulmonary arterial hypertension.NEDD9 将 靶向 以促进内皮纤维化和肺动脉高压。
Sci Transl Med. 2018 Jun 13;10(445). doi: 10.1126/scitranslmed.aap7294.
6
A pro-con debate: current controversies in PAH pathogenesis at the American Thoracic Society International Conference in 2017.赞成与反对观点辩论：2017 年美国胸科学会国际会议上关于肺动脉高压发病机制的当前争议。
Am J Physiol Lung Cell Mol Physiol. 2018 Oct 1;315(4):L502-L516. doi: 10.1152/ajplung.00150.2018. Epub 2018 Jun 7.
7
PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation.过氧化物酶体增殖物激活受体γ激动剂吡格列酮通过脂肪酸氧化逆转肺动脉高压并预防右心衰竭。
Sci Transl Med. 2018 Apr 25;10(438). doi: 10.1126/scitranslmed.aao0303.
8
Endothelial and Smooth Muscle Cell Interaction via FoxM1 Signaling Mediates Vascular Remodeling and Pulmonary Hypertension.FoxM1 信号介导的内皮和平滑肌细胞相互作用参与血管重构和肺动脉高压。
Am J Respir Crit Care Med. 2018 Sep 15;198(6):788-802. doi: 10.1164/rccm.201709-1835OC.
9
Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension.膜结合型 IL6R 的异位上调驱动肺动脉高压中的血管重构。
J Clin Invest. 2018 May 1;128(5):1956-1970. doi: 10.1172/JCI96462. Epub 2018 Apr 9.
10
Standards and Methodological Rigor in Pulmonary Arterial Hypertension Preclinical and Translational Research.肺动脉高压临床前和转化研究中的标准和方法学严谨性。
Circ Res. 2018 Mar 30;122(7):1021-1032. doi: 10.1161/CIRCRESAHA.117.312579.